How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design
A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.
Keep Reading
A turbine-inspired generator shows how overlooked industrial airflow could quietly become a new source of usable power
Updated
February 3, 2026 11:23 AM
Campus building of Chung-Ang University. PHOTO: CHUNG-ANG UNIVERSITY
Compressed air is used across factories, data centers and industrial plants to move materials, cool systems and power tools. Once it has done that job, the air is usually released — and its remaining energy goes unused.
That everyday waste is what caught the attention of a research team at Chung-Ang University in South Korea. They are investigating how this overlooked airflow can be harnessed to generate electricity instead of disappearing into the background.
Most of the world’s power today comes from systems like turbines, which turn moving fluids into energy or solar cells, which convert sunlight into electricity. The Chung-Ang team has built a device that uses compressed air to generate electricity without relying on traditional blades or sunlight.
At the center of the work is a simple question: what happens when high-pressure air spins through a specially shaped device at very high speed? The answer lies in the air itself. The researchers found that tiny particles naturally present in the air carry an electric charge. When that air moves rapidly across certain surfaces, it can transfer charge without physical contact. This creates electricity through a process known as the “particulate static effect.”
To use that effect, the team designed a generator based on a Tesla turbine. Unlike conventional turbines with blades, a Tesla turbine uses smooth rotating disks and relies on the viscosity of air to create motion. Compressed air enters the device, spins the disks at high speed and triggers charge buildup on specially layered surfaces inside.
What makes this approach different is that the system does not depend on friction between parts rubbing together. Instead, the charge comes from particles in the air interacting with the surfaces as they move past. This reduces wear and allows the generator to operate at very high speeds. And those speeds translate into real output.
In lab tests, the device produced strong electrical power. The researchers also showed that this energy could be used in practical ways. It ran small electronic devices, helped pull moisture from the air and removed dust particles from its surroundings.
The problem this research is addressing is straightforward.
Compressed air is already everywhere in industry, but its leftover energy is usually ignored. This system is designed to capture part of that unused motion and convert it into electricity without adding complex equipment or major safety risks.
Earlier methods of harvesting static electricity from particles showed promise, but they came with dangers. Uncontrolled discharge could cause sparks or even ignition. By using a sealed, turbine-based structure, the Chung-Ang University team offers a safer and more stable way to apply the same physical effect.
As a result, the technology is still in the research stage, but its direction is easy to see. It points toward a future where energy is not only generated in power plants or stored in batteries, but also recovered from everyday industrial processes.